Dezocine

CHEMBL1685 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

245.4 g/mol

LogP

3.7

Phase

4

An opioid analgesic used to treat moderate to severe pain by binding to opioid receptors in the central nervous system. It has both agonist and antagonist properties at different opioid receptor types.

Peso Molecular

245,3600 g/mol

LogP

3,70

TPSA

46,30 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Pain Management

Mecanismo de Ação

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@@]12CCCCC[C@@H](Cc3ccc(O)cc31)[C@@H]2N

InChI

InChI=1S/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1

Molecular Formula

C16H23NO

HBD / HBA

2 / 2

Ligações Rotacionáveis

0

Átomos Pesados

18

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An opioid analgesic used to treat moderate to severe pain by binding to opioid receptors in the central nervous system. It has both agonist and antagonist properties at different opioid receptor types.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Dezocine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1685. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3033053. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Dezocine no PillFYI

Estrutura

Dados Rápidos

Fórmula: C16H23NO

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.